A Randomized Double-Blind Controlled Study of Evitar for Reduction of Post-Myomectomy Adhesions (ICH-GCP Compliant)
Evitar™ (TTX 333): The first gold standard trial to successfully translate in-vitro mechanistic understanding of post-operative adhesion prevention of a molecule, L-Alanyl-L-Glutamine, into a potential treatment for human patients. Presentations: Society of Reproductive Investigations, San Diego 2018 & American Association of Gynecologic Laparoscopists, Las Vegas, 2018
